Summit Therapeutics and AstraZeneca announced a partnership on July 4, 2025, to collaborate on lung cancer drug development.
3 reports, 0 independent
Updated Jul 4
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Summit Therapeutics and AstraZeneca announced a partnership on July 4, 2025, to collaborate on lung cancer drug development.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Summit Therapeutics and AstraZeneca partnered on lung cancer drug development on July 4, 2025.
- AstraZeneca is actively marketing drugs in China, linked to lung cancer expertise in Shanghai.
Keep exploring
The entities involved
-
Summit Therapeutics
biopharmaceutical company
Nothing else this week.
-
AstraZeneca
British-Swedish pharmaceutical company
Related events
- AstraZeneca discontinued the eVOLVE-Lung02 trial on August 18, 2026.
- Alnylam Pharmaceuticals announced new partnerships with AstraZeneca for drug development and with Ionis Pharmaceuticals for clinical trials.
- Amgen acquired Horizon Therapeutics, a company whose portfolio included a drug discovered by AstraZeneca.
- AstraZeneca and Innate Pharma S.A. are collaborating on developing a lead pharmaceutical program.
- Amgen and AstraZeneca announced a collaborative development of a combination therapy.
Coverage
Newest first; wire copies grouped- Unknown outlet
- Unknown outlet
- Unknown outlet